Considering the complex immunomodulatory effects of pan-PI3K inhibitors, the application of selective isoform inhibitors might be able to simultaneously eradicate tumor cells and avoid the immunosuppressive effects of pan-PI3K inhibitors. This evidence concerns the gene PIK3CD and neoplasm.